International Nonproprietary Names prescription in a specialized public hospital in Egypt

Background: International Nonproprietary Names (INN) is prescribing the name of the active ingredient. Objective: This study aimed to investigate INN prescription rates and perceived barriers towards INN prescribing at a public Ministry of Health and Population (MOHP) hospital specialized in treating infectious diseases in Egypt. Methods: A retrospective chart review was conducted in a 280-bed specialized Ministry of Health Hospital in Alexandria, Egypt. Medications were described either as brand or generic based on WHO Essential Medicines List (EML) classification system and the Egyptian National Formulary. All physicians with prescribing authority in study hospital were administered a questionnaire composed of two sections. The first section explored the socio-demographic and work characteristics of the physicians, and the second section listed the barriers towards INN prescription. Results: Out of the 400 medical records reviewed, 2279 drugs were prescribed. About half of the medications (52.61%) were prescribed in INN. The medicines which were most frequently prescribed in INN were electrolytes solution (99.5%), laxatives (98.6%), and vitamins and minerals (85.2%) and coagulation medicines (82%). Other medications were exclusively prescribed in brand names as antispasmodics, antidiarrheal, dermatology and vascular insufficiency medications. Only 38.75% were trained using INNs to designate medications, about half of physicians (48%) reported that they rarely use INNs in their practice. The most frequently listed reasons for not prescribing in INN prescribing perceived by physicians were physicians being not familiar with INN (79.0%), doubts about the efficacy, safety, or quality of generic drugs (52.0%) and absence of educational programs regarding INN use (47.0%). Conclusion and Relevance: The current study illustrates only half of the prescriptions are prescribed using INN. A multifaceted approach using explicit policy for obligating INN prescription, together with educational sessions for physicians about the value of INN prescription and the bioequivalence of generic medications to their brand counterparts.

[1]  A. Faye,et al.  Evaluation of Prescribing Indicators in a Paediatric Population Seen in an Outpatient Consultation at the Gaspard Kamara Health Centre in 2019 (Senegal) , 2021, Pharmacy.

[2]  A. Amin,et al.  Generic Prescribing: The Egyptian semblance , 2021, Journal of advanced Biomedical and Pharmaceutical Sciences.

[3]  Micaela Pinho.  Prescribers’ and dispensers' views about generic medicines and international non-proprietary name prescribing – a mixed methods study in Portugal , 2020 .

[4]  F. Alqahtani,et al.  An Evaluation Of Antibiotics Prescribing Patterns In The Emergency Department Of A Tertiary Care Hospital In Saudi Arabia , 2019, Infection and drug resistance.

[5]  B. Yousef,et al.  Prescribing patterns of antimicrobials in the Internal Medicine Department of Ibrahim Malik Teaching Hospital in Khartoum, 2016 , 2019, The Pan African medical journal.

[6]  O. Spigset,et al.  Academic detailing as a method of continuing medical education , 2019, Advances in medical education and practice.

[7]  M. Gothard,et al.  The Effect of Pharmacy-Led, Small-Group Academic Detailing on Prescribing Patterns in an Ambulatory Care Clinic , 2018, The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians.

[8]  Y. Tefera,et al.  Evaluating patients’, physicians’ and pharmacy professionals’ perception and concern regarding generic medicines in Gondar town, northwest Ethiopia: A multi-stakeholder, cross-sectional survey , 2018, PloS one.

[9]  F. Gueyffier,et al.  INN or brand name drug prescriptions: a multilevel, cross-sectional study in general practice , 2018, European Journal of Clinical Pharmacology.

[10]  B. Godman,et al.  Assessment of prescribing practices at the primary healthcare facilities in Botswana with an emphasis on antibiotics: Findings and implications , 2017, International journal of clinical practice.

[11]  M. Slater,et al.  Examining patterns in medication documentation of trade and generic names in an academic family practice training centre , 2017, BMC medical education.

[12]  Steinar Madsen,et al.  Safety and efficiency of a new generic package labelling: a before and after study in a simulated setting , 2017, BMJ Quality & Safety.

[13]  M. Atif,et al.  Assessment of core drug use indicators using WHO/INRUD methodology at primary healthcare centers in Bahawalpur, Pakistan , 2016, BMC Health Services Research.

[14]  Samar F Farid,et al.  Perceptions of Egyptian physicians about drug shortage during political disturbances: Survey in Greater Cairo , 2016 .

[15]  M. Atif,et al.  WHO/INRUD prescribing indicators and prescribing trends of antibiotics in the Accident and Emergency Department of Bahawal Victoria Hospital, Pakistan , 2016, SpringerPlus.

[16]  K. Wyss,et al.  Drug prescribing patterns at primary health care level and related out-of-pocket expenditures in Tajikistan , 2016, BMC Health Services Research.

[17]  Akram Ahmad,et al.  Prescription patterns and appropriateness of antibiotics in the management of cough/cold and diarrhea in a rural tertiary care teaching hospital , 2016, Journal of pharmacy & bioallied sciences.

[18]  Tor Endestad,et al.  Package Design Affects Accuracy Recognition for Medications , 2016, Hum. Factors.

[19]  Y. Afify.  The pharmaceutical supply of brand and generic medicines in different rural and urban areas of Egypt. , 2016 .

[20]  K. Petrie,et al.  Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review , 2015, BMJ Open.

[21]  Christine Holmberg,et al.  Perceptions and Attitudes of Egyptian Health Professionals and Policy-Makers towards Pharmaceutical Sales Representatives and Other Promotional Activities , 2015, PloS one.

[22]  G. Heinze,et al.  Potential Savings in Prescription Drug Costs for Hypertension, Hyperlipidemia, and Diabetes Mellitus by Equivalent Drug Substitution in Austria: A Nationwide Cohort Study , 2015, Applied Health Economics and Health Policy.

[23]  Z. Y. Wong,et al.  Does educational intervention improve doctors’ knowledge and perceptions of generic medicines and their generic prescribing rate? A study from Malaysia , 2014, SAGE open medicine.

[24]  J. Montastruc,et al.  Interactions between Medical Residents and Drug Companies: A National Survey after the Mediator® Affair , 2014, PloS one.

[25]  Z. Y. Wong,et al.  Perspectives of physicians practicing in low and middle income countries towards generic medicines: a narrative review. , 2014, Health policy.

[26]  R. Busse,et al.  Recognition of pharmaceutical prescriptions across the European Union: a comparison of five Member States' policies and practices. , 2014, Health policy.

[27]  D. Chambers,et al.  Behaviour change interventions to promote prescribing of generic drugs: a rapid evidence synthesis and systematic review , 2014, BMJ Open.

[28]  O. Akl,et al.  WHO/INRUD drug use indicators at primary healthcare centers in Alexandria, Egypt , 2014 .

[29]  M. Hassali,et al.  The experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine use , 2013, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[30]  F. Alosaimi,et al.  Interactions between physicians and pharmaceutical sales representatives in Saudi Arabia , 2013, Annals of Saudi medicine.

[31]  Wenjie Zeng.  A price and use comparison of generic versus originator cardiovascular medicines: a hospital study in Chongqing, China , 2013, BMC Health Services Research.

[32]  M. Bennie,et al.  Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries , 2013, Expert review of pharmacoeconomics & outcomes research.

[33]  Generic Prescribing, Generic Substitution, and Therapeutic Substitution , 2013, Pediatric Clinical Practice Guidelines & Policies.

[34]  Steven Simoens,et al.  Demand-side policies to encourage the use of generic medicines: an overview , 2013, Expert review of pharmacoeconomics & outcomes research.

[35]  T. Khong,et al.  Making medicines evergreen , 2012, BMJ : British Medical Journal.

[36]  I. Masood,et al.  Perception and attitude of general practitioners regarding generic medicines in Karachi, Pakistan: A questionnaire based study , 2012, Southern med review.

[37]  D. Bates,et al.  An Educational Intervention to Improve Cost-Effective Care Among Medicine Housestaff: A Randomized Controlled Trial , 2012, Academic medicine : journal of the Association of American Medical Colleges.

[38]  A. Ciociola,et al.  The FDA's Generic-Drug Approval Process: Similarities to and Differences From Brand-Name Drugs , 2011, The American Journal of Gastroenterology.

[39]  D. Hughes,et al.  Generic and therapeutic substitutions in the UK: are they a good thing? , 2010, British journal of clinical pharmacology.

[40]  J. Kyriopoulos,et al.  Generic medicines: Greek physicians’ perceptions and prescribing practices , 2009, Journal of clinical pharmacy and therapeutics.

[41]  R. Grol,et al.  Quality circles to improve prescribing of primary care physicians. Three comparative studies , 2009, Pharmacoepidemiology and drug safety.

[42]  C. Teng,et al.  The effect of "group detailing" on drug prescribing in primary care. , 2008, The Medical journal of Malaysia.

[43]  N. Homedes,et al.  Generic drug policies in Latin America , 2005 .

[44]  J. Moatti,et al.  Delivering generics without regulatory incentives? Empirical evidence from French general practitioners about willingness to prescribe international non-proprietary names. , 2004, Health policy.

[45]  J. Moreno,et al.  Evaluación, mejora y monitorización de la prescripción de medicamentos genéricos , 2002 .

[46]  L. Keith,et al.  Generics: what's in a name? , 1998, International journal of fertility and women's medicine.

[47]  S. Vogler,et al.  Medicines reimbursement policies in Europe , 2018 .

[48]  N. Mansour,et al.  Rational Use of Drugs in Egypt According to the Standard WHOPrescribing Indicators: Pilot Baseline Situational Analysis , 2017 .

[49]  Value for Money in Health Spending , 2010 .

[50]  James M Hoffman,et al.  Medication Errors Caused by Confusion of Drug Names , 2003, Drug safety.

[51]  J. Weaver,et al.  The World Bank Group , 1986 .